NASDAQ:ACOR - Acorda Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $23.67
  • Forecasted Upside: 253.23 %
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.70
▲ +0.33 (5.18%)
1 month | 3 months | 12 months
Get New Acorda Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACOR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$23.67
▲ +253.23% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Acorda Therapeutics in the last 3 months. The average price target is $23.67, with a high forecast of $35.00 and a low forecast of $6.00. The average price target represents a 253.23% upside from the last price of $6.70.
Hold
The current consensus among 3 polled investment analysts is to hold stock in Acorda Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 3 sell ratings
7/28/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 3 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/13/2021CowenBoost Price Target$5.00 ➝ $35.00High
i
8/11/2020Jefferies Financial GroupReiterated RatingHold$6.00Low
i
5/6/2020HC WainwrightReiterated RatingNeutral$36.00 ➝ $30.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/9/2020HC WainwrightReiterated RatingHold$36.00High
i
Rating by Ram Selvaraju at HC Wainwright
2/16/2020JPMorgan Chase & Co.Reiterated RatingSellHigh
i
1/21/2020HC WainwrightReiterated RatingHold$30.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
1/16/2020CowenReiterated RatingBuy$60.00Medium
i
12/30/2019HC WainwrightReiterated RatingHold$36.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/23/2019HC WainwrightReiterated RatingHold$36.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
11/5/2019HC WainwrightReiterated RatingHold$36.00High
i
10/24/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$8.40High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/14/2019HC WainwrightDowngradeBuy ➝ Neutral$186.00 ➝ $36.00High
i
8/2/2019JPMorgan Chase & Co.Set Price TargetHold$42.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/2/2019Stifel NicolausLower Price TargetHold$72.00 ➝ $42.00High
i
8/2/2019WedbushLower Price TargetNeutral$48.00 ➝ $42.00High
i
Rating by L. Chico at Wedbush
8/2/2019Cantor FitzgeraldLower Price TargetNeutral$120.00 ➝ $72.00High
i
5/22/2019WedbushInitiated CoverageNeutral ➝ Neutral$72.00High
i
Rating by L. Chico at Wedbush
5/7/2019JPMorgan Chase & Co.Reiterated RatingHold$108.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
3/19/2019OppenheimerReiterated RatingHoldHigh
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/15/2019Cantor FitzgeraldReiterated RatingHold$120.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
1/23/2019HC WainwrightSet Price TargetBuy$198.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/14/2019HC WainwrightSet Price TargetBuy$198.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/7/2019CowenReiterated RatingBuy$180.00Medium
i
1/4/2019HC WainwrightReiterated RatingBuy$198.00High
i
Rating by Ram Selvaraju at HC Wainwright
1/2/2019OppenheimerSet Price TargetHold$108.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
1/2/2019Cantor FitzgeraldSet Price TargetHold$192.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
1/2/2019JPMorgan Chase & Co.Reiterated RatingHoldHigh
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/26/2018Raymond JamesReiterated RatingSellMedium
i
Rating by Laura Chico at Raymond James
12/26/2018JPMorgan Chase & Co.Reiterated RatingNeutral ➝ HoldHigh
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/24/2018OppenheimerSet Price TargetHold ACOR$108.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/24/2018Cantor FitzgeraldSet Price TargetHold ACOR$192.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
12/11/2018The Goldman Sachs GroupDowngradeNeutral ➝ Sell$114.00 ➝ $60.00High
i
11/5/2018HC WainwrightReiterated RatingBuy$180.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/4/2018Jefferies Financial GroupReiterated RatingHold$132.00Medium
i
10/31/2018JPMorgan Chase & Co.Set Price TargetHold$108.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/31/2018Cantor FitzgeraldSet Price TargetHold$192.00Low
i
Rating by Charles Duncan at Cantor Fitzgerald
10/24/2018HC WainwrightSet Price TargetBuy$168.00High
i
Rating by Ram Selvaraju at HC Wainwright
10/12/2018JPMorgan Chase & Co.Reiterated RatingHoldLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/5/2018Stifel NicolausLower Price TargetHold ➝ Hold$150.00 ➝ $114.00High
i
9/23/2018OppenheimerSet Price TargetHold$108.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/17/2018HC WainwrightSet Price TargetBuy$168.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/12/2018OppenheimerSet Price TargetHold$126.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/11/2018HC WainwrightSet Price TargetBuy$186.00High
i
Rating by Ram Selvaraju at HC Wainwright
9/10/2018Cantor FitzgeraldReiterated RatingHold$192.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
9/10/2018JPMorgan Chase & Co.Set Price TargetHold$120.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/23/2018Cantor FitzgeraldInitiated CoverageNeutral$192.00Medium
i
Rating by William Tanner at Cantor Fitzgerald
8/7/2018Stifel NicolausBoost Price TargetHold ➝ Hold$90.00 ➝ $150.00Low
i
8/6/2018HC WainwrightSet Price TargetBuy$186.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/2/2018OppenheimerSet Price TargetHold$126.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/2/2018CowenReiterated RatingBuy$180.00Medium
i
7/30/2018Cantor FitzgeraldSet Price TargetHold$102.00Low
i
Rating by William Tanner at Cantor Fitzgerald
7/26/2018HC WainwrightSet Price TargetBuy$186.00Low
i
Rating by Ram Selvaraju at HC Wainwright
7/25/2018OppenheimerSet Price TargetHold$126.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/25/2018JPMorgan Chase & Co.Reiterated RatingHoldLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
6/11/2018HC WainwrightSet Price TargetBuy$186.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/11/2018OppenheimerSet Price TargetHold$126.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/30/2018HC WainwrightSet Price TargetBuy$186.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/3/2018HC WainwrightSet Price TargetBuy$186.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/2/2018OppenheimerSet Price TargetHold$126.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/2/2018CowenReiterated RatingBuy$180.00High
i
4/2/2018HC WainwrightReiterated RatingBuy$186.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/21/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/16/2018OppenheimerSet Price TargetHold$126.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/15/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$150.60 ➝ $222.00High
i
Rating by Charles Duncan at Piper Jaffray Companies
2/7/2018The Goldman Sachs GroupUpgradeSell ➝ NeutralLow
i
1/31/2018OppenheimerBoost Price TargetMarket Perform ➝ Market Perform$108.00 ➝ $126.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
1/17/2018HC WainwrightReiterated RatingBuy ➝ Buy$204.00 ➝ $186.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
1/9/2018JPMorgan Chase & Co.Reiterated RatingHoldLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/14/2017HC WainwrightSet Price TargetBuy$204.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
11/28/2017Piper Jaffray CompaniesReiterated RatingNeutral$132.00Low
i
Rating by Charles Duncan at Piper Jaffray Companies
11/20/2017HC WainwrightSet Price TargetBuy$204.00N/A
i
Rating by R. Selvaraju at HC Wainwright
11/17/2017CowenReiterated RatingBuy$180.00N/A
i
11/16/2017Janney Montgomery ScottSet Price TargetHold$156.00 ➝ $102.00N/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
11/16/2017Raymond JamesDowngradeMarket Perform ➝ Underperform$42.00 ➝ $78.00N/A
i
11/16/2017Stifel NicolausDowngradeBuy ➝ Hold$156.00 ➝ $90.00N/A
i
11/15/2017JPMorgan Chase & Co.Lower Price TargetNeutral$114.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/15/2017SVB LeerinkLower Price TargetMarket Perform$108.00N/A
i
11/15/2017OppenheimerSet Price TargetHold$108.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/15/2017Cantor FitzgeraldLower Price TargetNeutral$108.00 ➝ $96.00N/A
i
11/9/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformN/A
i
11/9/2017OppenheimerInitiated CoverageMarket Perform$162.00N/A
i
11/8/2017HC WainwrightInitiated CoverageBuy$210.00N/A
i
Rating by R. Selvaraju at HC Wainwright
11/1/2017Jefferies Financial GroupBoost Price TargetHold$132.00 ➝ $150.00N/A
i
10/31/2017JPMorgan Chase & Co.Set Price TargetHold$144.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/31/2017Cantor FitzgeraldReiterated RatingHold$108.00N/A
i
10/6/2017The Goldman Sachs GroupReiterated RatingSell ➝ Sell$120.00N/A
i
9/28/2017Cantor FitzgeraldReiterated RatingHold$108.00Low
i
8/31/2017Stifel NicolausReiterated RatingBuy$180.00 ➝ $156.00Low
i
8/30/2017Janney Montgomery ScottReiterated RatingHold$108.00Low
i
Rating by Ken Trbovich at Janney Montgomery Scott
8/29/2017CowenReiterated RatingBuy$210.00Low
i
8/29/2017Cantor FitzgeraldReiterated RatingHold$108.00Low
i
7/28/2017Stifel NicolausReiterated RatingBuyLow
i
7/10/2017Jefferies Financial GroupInitiated CoverageHold ➝ Hold$132.00Medium
i
6/7/2017CowenReiterated RatingOutperform$210.00Low
i
Rating by Phil Nadeau at Cowen Inc
6/6/2017JPMorgan Chase & Co.Set Price TargetHold$144.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
4/3/2017CowenLower Price TargetOutperform$360.00 ➝ $210.00High
i
Rating by Phil Nadeau at Cowen Inc
4/3/2017The Goldman Sachs GroupReiterated RatingNeutral$132.00High
i
4/3/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$192.00 ➝ $144.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
4/3/2017Janney Montgomery ScottDowngradeBuy ➝ Neutral$228.00 ➝ $114.00High
i
Rating by Ken Trbovich at Janney Montgomery Scott
3/30/2017Stifel NicolausReiterated RatingBuy$180.00High
i
3/13/2017Janney Montgomery ScottUpgradeNeutral ➝ Buy$138.00 ➝ $228.00Low
i
Rating by Ken Trbovich at Janney Montgomery Scott
2/15/2017Cantor FitzgeraldReiterated RatingNeutral ➝ PositiveN/A
i
Rating by William Tanner at Cantor Fitzgerald
2/15/2017The Goldman Sachs GroupUpgradeSell ➝ NeutralN/A
i
2/14/2017CowenSet Price TargetBuy$360.00N/A
i
Rating by Phil Nadeau at Cowen Inc
2/14/2017Cantor FitzgeraldSet Price TargetHold$132.00N/A
i
Rating by William Tanner at Cantor Fitzgerald
2/9/2017JPMorgan Chase & Co.Set Price TargetBuy$192.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/22/2017JPMorgan Chase & Co.Reiterated RatingBuy$192.00N/A
i
1/9/2017CowenReiterated RatingBuy$360.00N/A
i
Rating by Phil Nadeau at Cowen Inc
1/9/2017Cantor FitzgeraldReiterated RatingHold$126.00N/A
i
1/8/2017Evercore ISISet Price TargetHold$138.00N/A
i
Rating by John Scotti at Evercore ISI
1/3/2017CowenSet Price TargetBuy$360.00N/A
i
Rating by Phil Nadeau at Cowen Inc
12/21/2016Cantor FitzgeraldReiterated RatingNeutralN/A
i
12/19/2016Janney Montgomery ScottInitiated CoverageNeutral$138.00N/A
i
12/15/2016Cantor FitzgeraldInitiated CoverageNeutral$126.00N/A
i
11/30/2016JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightN/A
i
11/23/2016SVB LeerinkReiterated RatingMarket PerformN/A
i
Rating by P. Matteis at SVB Leerink LLC
10/27/2016CowenReiterated RatingBuy$360.00N/A
i
Rating by Phil Nadeau at Cowen Inc
10/4/2016SVB LeerinkInitiated CoverageMarket Perform$150.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
8/25/2016Stifel NicolausReiterated RatingBuyN/A
i
8/25/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
8/25/2016CowenReiterated RatingOutperform$390.00N/A
i
Rating by Phil Nadeau at Cowen Inc
6/1/2016AegisBoost Price TargetBuy$240.00 ➝ $312.00N/A
i
5/22/2016SVB LeerinkReiterated RatingHold$186.00 ➝ $174.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
5/20/2016CowenReiterated RatingOutperform$390.00 ➝ $360.00N/A
i
Rating by Phil Nadeau at Cowen Inc
5/20/2016Evercore ISIReiterated RatingHold$192.00N/A
i
4/28/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
4/17/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
3/30/2016The Goldman Sachs GroupInitiated CoverageSell$138.00N/A
i
3/14/2016Stifel NicolausLower Price TargetBuy$288.00N/A
i
2/12/2016Stifel NicolausReiterated RatingBuy$318.00N/A
i
Rating by Thomas Shrader at Stifel Nicolaus
1/19/2016SVB LeerinkReiterated RatingMarket Perform$210.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
(Data available from 1/18/2016 forward)
Acorda Therapeutics logo
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Read More

Today's Range

Now: $6.70
$6.03
$6.72

50 Day Range

MA: $4.14
$0.69
$6.37

52 Week Range

Now: $6.70
$2.53
$15.30

Volume

60,475 shs

Average Volume

4,368,400 shs

Market Capitalization

$53.57 million

P/E Ratio

1.21

Dividend Yield

N/A

Beta

0.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Acorda Therapeutics?

The following equities research analysts have issued reports on Acorda Therapeutics in the last twelve months: Cowen Inc, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., and Zacks Investment Research.

What is the current price target for Acorda Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Acorda Therapeutics in the last year. Their average twelve-month price target is $23.67, suggesting a possible upside of 253.2%. Cowen Inc has the highest price target set, predicting ACOR will reach $35.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $6.00 for Acorda Therapeutics in the next year.

What is the current consensus analyst rating for Acorda Therapeutics?

Acorda Therapeutics currently has 1 sell rating and 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ACOR, but not buy more shares or sell existing shares.

What other companies compete with Acorda Therapeutics?

How do I contact Acorda Therapeutics' investor relations team?

Acorda Therapeutics' physical mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company's listed phone number is 914-347-4300. The official website for Acorda Therapeutics is www.acorda.com.